Endonovo Therapeutics, Inc.
Cash Flow Statement
| Line Item | Sep 2023 | Jun 2023 | Mar 2023 | Dec 2022 | Sep 2022 | Jun 2022 | Mar 2022 | Dec 2021 |
|---|---|---|---|---|---|---|---|---|
| Operating Activities | ||||||||
| Net Income | $-766.2K | $2.1M | $7.2M | $-12.9M | $-603.4K | $-2.5M | $-2.4M | $2.4M |
| Depreciation & Amortization | — | — | — | $161.7K | $161.7K | $161.7K | $161.7K | $161.7K |
| Depreciation | — | — | — | — | — | — | — | $0 |
| Amortization | $161.7K | $161.7K | $161.7K | $161.7K | $161.7K | $161.7K | $161.7K | $161.7K |
| Stock-Based Compensation | $0 | $3.4K | $2.6K | — | — | — | — | $-61.0K |
| Net Cash from Operating Activities | $-65.4K | $-165.8K | $-173.2K | $-225.5K | $-123.9K | $-206.5K | $-123.0K | $-391.3K |
| Investing Activities | ||||||||
| Capital Expenditures | — | — | — | — | — | — | — | — |
| Business Acquisitions | — | — | — | — | — | — | — | — |
| Net Cash from Investing Activities | — | — | — | — | — | — | — | — |
| Financing Activities | ||||||||
| Dividends Paid | — | — | — | — | — | — | — | — |
| Stock Repurchases | — | — | — | — | — | — | — | — |
| Net Cash from Financing Activities | $32.8K | $187.5K | $184.0K | $202.5K | $147.0K | $146.5K | $97.0K | $471.5K |
| Net Change in Cash | $-32.6K | $21.7K | $10.8K | $-23.0K | $23.1K | $-60.0K | $-26.0K | $80.2K |
| Free Cash Flow | — | — | — | — | — | — | — | — |